XML 19 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Net sales $ 14,240 $ 12,682 $ 11,888
Cost of products sold 4,345 3,956 3,711
Gross profit 9,896 8,727 8,177 Close
Operating expenses:       Close
Selling, general and administrative expenses 5,190 4,520 4,359 Close
Research and development expenses 1,414 1,323 1,204 Close
Royalty expense 46 47 49 Close
Amortization expense 828 803 741 Close
Intangible asset impairment charges 58 132 370 Close
Contingent consideration net expense (benefit) 58 35 (136) Close
Restructuring net charges (credits) 69 24 40 Close
Litigation-related net charges (credits) (111) 173 430 Close
Loss (Gain) on Disposal of Businesses and Assets 0 22 (78) Close
Operating expenses 7,553 7,078 6,978 CloseClose
Total Operating Expenses 15105.0 14157.0 13957.0 0 0 Close
Operating income (loss) 2,343 1,649 1,199 Close
Other income (expense):       Close
Interest expense (265) (470) (341) Close
Total Other Income Expenses -358.0 -508.0 -123.0 0 0 Close
Other, net (93) (38) 218 CloseClose
Income (loss) before income taxes 1,985 1,141 1,076 Close
Income tax expense (benefit) 393 443 36 Close
Net income (loss) 1,592 698 1,041 Close
Preferred stock dividends 23 55 55
Net income (loss) attributable to noncontrolling interests (1) 0 0
Net income (loss) attributable to Boston Scientific common stockholders $ 1,570 $ 642 $ 985
Net income (loss) per common share — basic $ 1.08 $ 0.45 $ 0.69
Net income (loss) per common share — diluted $ 1.07 $ 0.45 $ 0.69
Weighted-average shares outstanding      
Basic 1,453,000 1,430,500 1,422,300
Diluted 1,463,500 1,439,700 1,433,800